Member Info for Jatw

130p looks like a consensus forecast at present with potential upside.
The HY announcement listed adjusted EBITDA of 3.5m, so say 7m at FY meaning currently trading at 14x EBITDA (adjusted). If that is what singer is using then a drop to 5x implies that an average rating would produce a substantial SP uplift.

Can you shed any light on this Rivaldo?

Perhaps unsurprisingly the process is later this year an d is not expected until December. Likely there will be more drugs added and price reductions to retain a listing.

HCM will have already submitted repricing offer let’s hope it is a minimal change as it will only be down. Let’s hope the sales are improving following transfer from Lilly to Chi-med.

So the ADS listing will raise about £100m a dilution of slightly above 3%.
Underwriters have a 15% over allotment allocation
Expect it to be priced this week.

BBD do you have a winner over the year?

FIL a appears to be Fidelity International Limited.....so more likely an investment position rather than the beginnings of a strategic investor.

With NAV above 200p, you would think there is value here...Recent SH may be happy with 80p. LTHs would like a lot more.
An early bidder may get a bargain, leave it too long and recovery From Covid might have set in

Lots of negatives for the UK environment at the moment.....as recently described by IMF and Moody’s.
Increased borrowing, lack of growth, EU trade likely to cause inflation blip.
Happy to hold Pru with its growth Asian franchise

Wealth Managers that own the client relationship have much larger margins than the asset manager that delivers the performance for the client - in a rational world it would be the other way round....with those that create the wealth being rewarded over the sales organisation. WM have such a knowledge advantage over customers that they can easily pull the wool over their eyes.

Wealth Management has to justify its cost. Regulators need to focus on WM to ensure it does.

That is a long list of research targets. Any you would recommend looking at?

New highs very close now....esp if Pershing has slowed its selling.

The mysterious FIL from Bermuda (an insurance hub) has appeared with a 5% holding. Would not be surprised to see this holding grow and after appointing directors lead on to a bid - or maybe they just see value and will be gone in a year or less.

The 250m bond is more important, it is a higher capital tier than the 75m of bonds redeemed which may be the main reason for the issue. The coupon is a stiff 7% so it is hard to see how Just will make money on the investment of this cash.

Firmer foundations are worth having. Would be nice to see a run up above 50p in the next few weeks but brexit and Covid look like dragging the market lower

I think we need not worry too much about the SP at the moment.....the market is often more excited about new things. This company has a bright future.....if you want to trade and second guess the market good luck. Otherwise I am thinking that in 5years the company may well double in value (NB different to double the SP) and if it only treads water it means the global economy has been v poor, so that may well be a better return than many can offer.
The SP has traded 480-520 for some time. Entering or topping up at current levels is decent value. Take advantage and add steadily is my current view.

I have used a metaphor of a fast tortoise before - I think this this is a get steadily wealthier investment. There are others out there that will go faster in The short term, but we are now in testing times and there may be major market setbacks in the next few months....This stake in the future may be more stable than most.

50k purchase, usually Directors can recognise value.

Just ahead Of net client cash flow turning positive would be an optimal time to buy.....

Should be soon maybe this coming quarter or early 21 depending on pandemic progress and US policy following election.

Thanks for posting.....it would be helpful if they wrote a few lines about what has changed.
From an early scan I think these are the updates:
More detail of the approach to Surufatinib approval
Fresco 2 charts in Fruquintinib section

Could be updates to the early stage pipeline and news targets.

While a 15% jump would be welcome, there is no RNS and no AIM reaction, so we have to assume an error/ anomaly.
Next Big news likely to be approval of surufatinib in China....or Savolitinib strategy.

Two RNS show Pershing has been a seller of late from 9.4% to 7.2%.
This perhaps explains why the SP has stalled against a large willing seller.
They may have another % or two to sell down, the market has absorbed this pressure so could progress once Pershing has reduced its stake.....can’t see them wanting to exit completely, more a case of portfolio management and banking some gains.

Def not a Kate. But I assume that is some autocorrect spelling error.

I am being proven wrong at the moment....and happy for LTH to be wrong.
Could be the other side f the coin....walk the SP up so that the discount looks like a bargain when sold in The US. Still think there will be a discount when the price is announced and better to buy afterwards.

https://apple.news/ARAmtJ-BTT8-rYXkJQCZGqA
Also available here
https://www.scmp.com/business/companies/article/3104789/chinas-health-care-sector-consolidation-produce-global-champions

Is this to be the fate of HCM?
Prey or predator? More likely to be sold than expanded by CKHH.

What will drive a further rise?
Covid worsening driving additional demand in Q420.
Mouthwash trial may be newsworthy.
Acquisition of new products?

Likely to be a safe haven amongst smaller companies given its products.